Sionna Therapeutics reported a net loss of $75.3 million for 2025, up 22% from the $61.7 million loss recorded in 2024, and a quarterly loss of $20.4 million versus $15.8 million in the prior year’s fourth quarter. The company’s research and development spend rose to $60.3 million, a 5% increase driven by continued investment in its NBD1 stabilizer pipeline, while general and administrative costs climbed to $28.7 million, an 86% jump largely attributable to personnel expansion and professional fees associated with the company’s public‑company status.
Cash, cash equivalents and marketable securities totaled $310.3 million as of December 31, 2025, giving Sionna a runway that extends into 2028 under current burn rates. The company reiterated that the cash position is sufficient to fund operations through 2028, while noting that additional capital may be required to advance its clinical programs toward the mid‑2026 readouts.
Sionna highlighted progress in its pipeline, noting that Phase 1 data for its NBD1 stabilizers SION‑719 and SION‑451 were positive. Topline readouts for the ongoing Phase 2a PreciSION CF trial and Phase 1 dual‑combination trial are expected in mid‑2026. These results are critical milestones for validating the company’s novel mechanism and for positioning the company for potential partnership or acquisition opportunities.
Management emphasized the importance of the strong cash runway and the upcoming mid‑2026 catalysts. The company’s leadership highlighted that the positive Phase 1 data and the anticipated Phase 2a and dual‑combination readouts will be key to demonstrating the clinical value of its NBD1 stabilizer platform and to attracting strategic partners or buyers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.